• China Biologic Products Inc., of Beijing, said subsidiary Shandong Taibang Biological Products Co. Ltd. received approval from Chinese regulators to begin clinical trials of its human fibrinogen to treat congenital fibrinogen deficiency and acquired fibrinogen deficiency.